400 related articles for article (PubMed ID: 35525929)
1. Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study.
Eser K; Önder AH; Sezer E; Çil T; İnal A; Öztürk B; Erçolak V; Duman BB; Çelik H; Köşeci T; Kesen O
BMC Cancer; 2022 May; 22(1):516. PubMed ID: 35525929
[TBL] [Abstract][Full Text] [Related]
2. Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients.
Del Re M; Omarini C; Diodati L; Palleschi M; Meattini I; Crucitta S; Lorenzini G; Isca C; Fontana A; Livi L; Piacentini F; Fogli S; De Giorgi U; Danesi R
ESMO Open; 2021 Oct; 6(5):100231. PubMed ID: 34509802
[TBL] [Abstract][Full Text] [Related]
3. Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib.
Del Re M; Crucitta S; Omarini C; Bargagna I; Mongillo M; Palleschi M; Stucci S; Meattini I; D'Onofrio R; Lorenzini G; Biondani P; De Giorgi U; Porta C; Livi L; Natalizio S; Fontana A; Giontella E; Angelini L; Fogli S; Danesi R
Breast; 2022 Dec; 66():157-161. PubMed ID: 36283134
[TBL] [Abstract][Full Text] [Related]
4. Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer?
Odabas H; Dogan A; Ozcelik M; Yildirim S; Ozkerim U; Turan N; Yildirim ME; Gumus M
Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984558
[No Abstract] [Full Text] [Related]
5. The effect of concomitant use of proton pump inhibitors with CDK 4/6 inhibitors on survival in metastatic breast cancer.
Çağlayan D; Koçak MZ; Geredeli Ç; Tatlı AM; Göksu SS; Eryılmaz MK; Araz M; Artaç M
Eur J Clin Pharmacol; 2023 Feb; 79(2):243-248. PubMed ID: 36520173
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
Mistry R; May JR; Suri G; Young K; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya S; Mishra D; Bhattacharyya D; Dalal AA
J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study.
Yıldırım HÇ; Kutlu Y; Mutlu E; Aykan MB; Korkmaz M; Yalçın S; Şakalar T; Celayir ÖM; Kayıkçıoğlu E; Aslan F; Hafızoğlu E; Altıntaş YE; Keskinkılıç M; Chalabiyev E; Çelebi A; Dursun B; Kapar C; Özen M; Acar Ö; Dülgar Ö; Kut E; Biter S; Kus F; Almuradova E; Erdoğan AP; Saray S; Güven DC; Şimşek ET; Üskent N; Kemal Y; Çakar B; Açıkgöz Ö; Kılıçkap S; Aksoy S
Int J Clin Oncol; 2024 Mar; 29(3):258-265. PubMed ID: 38310597
[TBL] [Abstract][Full Text] [Related]
8. Concomitant Use of Proton Pump Inhibitors and Palbociclib Among Patients With Breast Cancer.
Lee JE; Kwon SH; Kwon S; Jung HI; Nam JH; Lee EK
JAMA Netw Open; 2023 Jul; 6(7):e2324852. PubMed ID: 37477917
[TBL] [Abstract][Full Text] [Related]
9. Effect of Concurrent Proton Pump Inhibitors With Palbociclib Tablets for Metastatic Breast Cancer.
Schieber T; Steele S; Collins S; Berger M; Fleming M; McLaughlin E; Sudheendra P; Vargo C
Clin Breast Cancer; 2023 Aug; 23(6):658-663. PubMed ID: 37296062
[TBL] [Abstract][Full Text] [Related]
10. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
[TBL] [Abstract][Full Text] [Related]
11. Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women.
Gupta N; Gupta D; Dixit J; Mehra N; Singh A; Krishnamurthy MN; Jyani G; Rajsekhar K; Kalaiyarasi JP; Roy PS; Malik PS; Mathew A; Malhotra P; Gupta S; Kumar L; Kataki A; Prinja S
Appl Health Econ Health Policy; 2022 Jul; 20(4):609-621. PubMed ID: 35534752
[TBL] [Abstract][Full Text] [Related]
12. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
[TBL] [Abstract][Full Text] [Related]
13. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
[TBL] [Abstract][Full Text] [Related]
14. Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study.
Waller J; Mitra D; Mycock K; Taylor-Stokes G; Milligan G; Zhan L; Iyer S
J Glob Oncol; 2019 May; 5():JGO1800239. PubMed ID: 31050919
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of palbociclib and ribociclib in patients with estrogen and/or progesterone receptor positive, HER2 receptor negative metastatic breast cancer in routine clinical practice.
Rath S; Elamarthi P; Parab P; Gulia S; Nandhana R; Mokal S; Kembhavi Y; Perumal P; Bajpai J; Ghosh J; Gupta S
PLoS One; 2021; 16(7):e0253722. PubMed ID: 34292933
[TBL] [Abstract][Full Text] [Related]
16. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
17. Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.
Mangini NS; Wesolowski R; Ramaswamy B; Lustberg MB; Berger MJ
Ann Pharmacother; 2015 Nov; 49(11):1252-60. PubMed ID: 26324355
[TBL] [Abstract][Full Text] [Related]
18. Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy.
Varella L; Eziokwu AS; Jia X; Kruse M; Moore HCF; Budd GT; Abraham J; Montero AJ
Breast Cancer Res Treat; 2019 Jul; 176(2):429-434. PubMed ID: 30895534
[TBL] [Abstract][Full Text] [Related]
19. Proton Pump Inhibitors and Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Breast Cancer.
Takahashi K; Uozumi R; Mukohara T; Hayashida T; Iwabe M; Iihara H; Kusuhara-Mamishin K; Kitagawa Y; Tsuchiya M; Kitahora M; Nagayama A; Kosaka S; Asano-Niwa Y; Seki T; Ohnuki K; Suzuki A; Ono F; Futamura M; Kawazoe H; Nakamura T
Oncologist; 2024 Jun; 29(6):e741-e749. PubMed ID: 38340010
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
Zhang B; Long EF
Breast Cancer Res Treat; 2019 Jun; 175(3):775-779. PubMed ID: 30847728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
